Key result
DOAC use linked to ~52% lower risk of early stroke recurrence in AF patients.
Why the study?
Early recurrence after an acute stroke event in patients with AF presents a therapeutic challenge due to balancing ischemic prevention with hemorrhagic risk.
What is the incidence and what are the predictors of early stroke recurrence within 6 months in patients with atrial fibrillation presenting with a first-ever acute stroke event?
Cohort (n=1,795)
No
What is the incidence and what are the predictors of early stroke recurrence within 6 months in patients with atrial fibrillation presenting with a first-ever acute stroke event?
Early stroke recurrence in AF patients occurs predominantly within the first 30 days, and early DOAC initiation is associated with a significantly reduced risk of recurrence.
Introduction Early recurrence (ER) after an acute stroke event (ASE; ischemic or hemorrhagic) in patients with atrial fibrillation (AF) presents a therapeutic challenge due to the need to balance ischemic prevention with hemorrhagic risk. This study aimed to quantify ER incidence, both ischemic and hemorrhagic, and identify its predictors using real-world data from a prospective registry. Patients and methods Retrospective analysis of patients with AF, either known or detected within 6 months, who were admitted for a first-ever ASE to a tertiary stroke center between 2005 and 2024. ER was defined as any recurrent event within 6 months. Baseline characteristics, CHA2DS2-VASc score, CHADS-VA score, stroke severity, anticoagulation type, AF detection timing, and monitoring duration were recorded. Cox and Fine-Gray models identified independent predictors. Results Among 1795 patients, 108 (6.0%) experienced ER. The cumulative incidence was 6.3% (95% CI 5.1–7.4), and most events occurred within the first 30 days. Independent predictors included higher CHA2DS2-VASc score (sHR = 1.252, p = 0.023), lower initial stroke severity (sHR = 0.918, p < 0.001), concomitant stroke etiologies (sHR = 2.008, p = 0.001), and AF detected within 30 days after stroke (sHR = 1.644, p = 0.026). DOAC use was protective (sHR = 0.484, p = 0.003), while VKA showed a non-significant trend (sHR = 0.637, p = 0.068). Interaction analysis showed increased recurrence risk only in non-anticoagulated patients with AF detected after stroke. These findings were consistent across sensitivity analyses restricted to ischemic stroke, incorporating time-dependent anticoagulation, or comparing CHADS-VA and CHA2DS2-VASc scores. Conclusions ER, predominantly ischemic, occurred mainly within 30 days. Risk factors included AF detection timing, CHA2DS2-VASc score, stroke severity, concomitant causes, and anticoagulation status, supporting early risk stratification and DOAC initiation.
No takes yet. Share an insight, caveat, or question.
Guisado‐Alonso et al. (2026) conducted a cohort in Atrial fibrillation and acute stroke event (n=1,795). Direct oral anticoagulants (DOACs) vs. No DOAC use was evaluated on Early recurrence (any recurrent event within 6 months) (sHR 0.484, p=0.003). Early stroke recurrence occurred in 6.0% of patients with atrial fibrillation within 6 months, and DOAC use was associated with a significantly lower risk of recurrence (sHR 0.484, p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: